Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Proximal tubular damage (PTD) refers to the structural or functional impairment of the proximal convoluted tubules in the kidney. These segments are vital for the reabsorption of the vast majority of filtered solutes, including glucose, amino acids, and electrolytes. PTD is a common pathological hallmark of acute kidney injury (AKI) and is frequently induced by ischemia or nephrotoxic agents such as cisplatin, aminoglycosides, and tenofovir. While it represents a critical clinical endpoint and a major safety concern in drug development (nephrotoxicity), it is a physiological state or pathological outcome rather than a specific molecular target like a receptor or enzyme. Therapeutic strategies typically focus on preventing this damage by targeting underlying inflammatory or oxidative pathways rather than the 'damage' itself.
Not applicable as this is a pathological state rather than a molecular target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Proximal tubular damage (PTD).